Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults

In a placebo-controlled, phase 2–3 trial, one dose of mRNA-1345 led to a lower incidence of RSV disease among adults 60 years of age or older. Solicited local and systemic adverse reactions occurred more often with the vaccine.

Saved in:
Bibliographic Details
Published in:The New England journal of medicine Vol. 389; no. 24; pp. 2233 - 2244
Main Authors: Wilson, Eleanor, Goswami, Jaya, Baqui, Abdullah H., Doreski, Pablo A., Perez-Marc, Gonzalo, Zaman, Khalequ, Monroy, Jorge, Duncan, Christopher J.A., Ujiie, Mugen, Rämet, Mika, Pérez-Breva, Lina, Falsey, Ann R., Walsh, Edward E., Dhar, Rakesh, Wilson, Lauren, Du, Jiejun, Ghaswalla, Parinaz, Kapoor, Archana, Lan, Lan, Mehta, Shraddha, Mithani, Runa, Panozzo, Catherine A., Simorellis, Alana K., Kuter, Barbara J., Schödel, Florian, Huang, Wenmei, Reuter, Caroline, Slobod, Karen, Stoszek, Sonia K., Shaw, Christine A., Miller, Jacqueline M., Das, Rituparna, Chen, Grace L.
Format: Journal Article
Language:English
Published: United States Massachusetts Medical Society 14.12.2023
Subjects:
Aged
Aging
Aging General
Antibodies, Viral
Chronic obstructive pulmonary disease
Clinical Medicine
Clinical Medicine General
Clinical trials
Confidence intervals
Critical Care
Critical Care General
Double-Blind Method
Geriatrics
Glycoproteins
Humans
Infections
Infectious Disease
Infectious Disease General
Middle Aged
Morbidity
mRNA
mRNA Vaccines - adverse effects
mRNA Vaccines - therapeutic use
Older people
Outpatient-Based Clinical Medicine
Placebos
Product development
Pulmonary
Respiratory diseases
Respiratory syncytial virus
Respiratory Syncytial Virus Infections - epidemiology
Respiratory Syncytial Virus Infections - prevention & control
Respiratory Syncytial Virus Vaccines - adverse effects
Respiratory Syncytial Virus Vaccines - therapeutic use
Respiratory Syncytial Virus, Human - genetics
Respiratory tract diseases
Respiratory Tract Diseases - diagnosis
Respiratory Tract Diseases - epidemiology
Respiratory Tract Diseases - prevention & control
Safety
Side effects
Statistical analysis
Success
Treatment Outcome
Vaccine efficacy
Vaccines
Viral Infections
ISSN:0028-4793, 1533-4406, 1533-4406
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In a placebo-controlled, phase 2–3 trial, one dose of mRNA-1345 led to a lower incidence of RSV disease among adults 60 years of age or older. Solicited local and systemic adverse reactions occurred more often with the vaccine.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa2307079